Sharechat Logo

Rua Bioscience Limited (NZX: RUA) Shareholders Approve Zalm Therapeutics Share Issue

Wednesday 19th January 2022

Text too small?

At a Special Meeting held online today, Wednesday 19 January 2022, Rua Bioscience shareholders voted in favour of Rua acquiring Zalm Therapeutics. Shareholders were asked to vote on a resolution being:

That the issue of:

• 8,140,000 new ordinary shares (Initial Shares); and

• 16,280,000 equity securities having the right to convert into ordinary shares on achievement of the milestones described in the explanatory notes (Performance Shares) to the shareholders of Zalm Therapeutics Limited (which may together eventually result in those subscribers holding 28,735,632 fully paid ordinary shares in the Company) be approved for all purposes, including for the purposes of NZX Listing Rule 4.2.1(a).

As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolution was passed by the required majority, and the result of the voting is attached.

Please see the link below for details

Meeting Results Announcement

Source: Rua Bioscience Limited

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Gentrack Group Limited Half-Year Results
Turners delivers record earnings result for FY22
NPH - 2022 Half Year Results
24th May 2022 Morning Report
Ryman Healthcare plans new village in Rolleston
My Food Bag releases FY22 Results
Oceania positioned for growth
Ryman Healthcare buys retirement village site in Melbourne
Dr David Kerr to retire from Ryman Healthcare Board